Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Globo H is a hexasaccharide glycosphingolipid (Fucα1→2Galβ1→3GalNAcβ1→3Galα1→4Galβ1→4Glcβ1→Cer) that serves as a prominent tumor-associated carbohydrate antigen (TACA) (Huang et al., 2013, PNAS) [1]. It is overexpressed on the outer cell membrane of various epithelial cancers, including breast, prostate, lung, and ovarian cancers (Zhang et al., 1997, Cancer Res) [2]. In contrast, its expression on normal tissues is highly restricted, primarily found on the apical surface of epithelial cells in secretory organs such as the pancreas and salivary glands (OBI Pharma) [3]. This differential expression pattern makes it an attractive target for selective cancer therapies. In the context of malignancy, Globo H is thought to play roles in promoting tumor cell survival, migration, and angiogenesis (Chang et al., 2015) [4]. Therapeutic strategies targeting Globo H include active immunotherapy via carbohydrate-based vaccines, such as Adagloxad simolenin (OBI-822), which are designed to stimulate the patient's immune system to produce anti-Globo H antibodies (ClinicalTrials.gov) [5]. Additionally, passive immunotherapy approaches using humanized monoclonal antibodies (e.g., OBI-888) and antibody-drug conjugates (e.g., OBI-999) are being developed to directly target and kill Globo H-expressing cells (OBI Pharma) [3]. These interventions leverage mechanisms like antibody-dependent cellular cytotoxicity (ADCC) and complement-dependent cytotoxicity (CDC) to eliminate tumor cells. Clinical development of these agents focuses on patients whose tumors show high Globo H expression as determined by immunohistochemistry.
Induction of a humoral immune response through active vaccination, or direct tumor cell killing via antibody-dependent cellular cytotoxicity (ADCC), complement-dependent cytotoxicity (CDC), and targeted delivery of cytotoxic payloads using antibody-drug conjugates.
3 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Globo H glycolipid antigen (Globo H).